Equities research analysts expect that Gilead Sciences, Inc. (NASDAQ:GILD) will announce sales of $5.33 billion for the current quarter, according to Zacks Investment Research. Eight analysts have made estimates for Gilead Sciences’ earnings. The lowest sales estimate is $5.03 billion and the highest is $5.58 billion. Gilead Sciences reported sales of $5.09 billion during the same quarter last year, which indicates a positive year over year growth rate of 4.7%. The company is scheduled to report its next earnings report on Tuesday, May 7th.
On average, analysts expect that Gilead Sciences will report full-year sales of $22.03 billion for the current year, with estimates ranging from $21.45 billion to $22.50 billion. For the next year, analysts forecast that the firm will report sales of $22.61 billion, with estimates ranging from $21.43 billion to $23.45 billion. Zacks’ sales calculations are a mean average based on a survey of analysts that cover Gilead Sciences.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Monday, February 4th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.70 by ($0.26). The company had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.52 billion. Gilead Sciences had a net margin of 24.65% and a return on equity of 37.03%. The firm’s revenue for the quarter was down 2.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.78 earnings per share.
A number of brokerages have recently issued reports on GILD. ValuEngine raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, December 1st. BidaskClub raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Thursday, November 8th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, November 14th. Oppenheimer reissued a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, November 14th. Finally, Citigroup reissued a “buy” rating and set a $100.00 target price on shares of Gilead Sciences in a research note on Tuesday, February 5th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. Gilead Sciences presently has a consensus rating of “Hold” and a consensus price target of $83.59.
Shares of GILD traded down $1.43 during trading hours on Thursday, reaching $65.55. 5,606,896 shares of the company traded hands, compared to its average volume of 7,773,477. The firm has a market capitalization of $86.36 billion, a P/E ratio of 10.66, a P/E/G ratio of 4.20 and a beta of 1.19. Gilead Sciences has a 12-month low of $60.32 and a 12-month high of $82.71. The company has a current ratio of 3.36, a quick ratio of 3.29 and a debt-to-equity ratio of 1.09.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 28th. Investors of record on Friday, March 15th will be paid a $0.63 dividend. The ex-dividend date of this dividend is Thursday, March 14th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.57. This represents a $2.52 dividend on an annualized basis and a yield of 3.84%. Gilead Sciences’s dividend payout ratio is 37.07%.
In related news, Director Gayle E. Wilson sold 19,068 shares of the company’s stock in a transaction dated Tuesday, February 19th. The shares were sold at an average price of $67.08, for a total value of $1,279,081.44. Following the completion of the sale, the director now directly owns 143,567 shares of the company’s stock, valued at $9,630,474.36. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director John C. Martin sold 50,000 shares of the company’s stock in a transaction dated Monday, December 3rd. The stock was sold at an average price of $71.20, for a total transaction of $3,560,000.00. Following the completion of the sale, the director now directly owns 2,877,762 shares of the company’s stock, valued at $204,896,654.40. The disclosure for this sale can be found here. 1.16% of the stock is owned by corporate insiders.
A number of large investors have recently added to or reduced their stakes in the stock. B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund purchased a new stake in shares of Gilead Sciences during the fourth quarter valued at about $882,000. Surevest Inc. purchased a new stake in shares of Gilead Sciences during the fourth quarter valued at about $326,000. Nordea Investment Management AB lifted its position in shares of Gilead Sciences by 14.1% during the fourth quarter. Nordea Investment Management AB now owns 1,026,174 shares of the biopharmaceutical company’s stock valued at $64,186,000 after buying an additional 127,140 shares during the last quarter. PFG Advisors purchased a new stake in shares of Gilead Sciences during the fourth quarter valued at about $468,000. Finally, Executive Wealth Management LLC purchased a new stake in shares of Gilead Sciences during the fourth quarter valued at about $97,000. 77.76% of the stock is owned by institutional investors.
Gilead Sciences Company Profile
Gilead Sciences, Inc discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Featured Article: How prevalent are 12b-1 fees?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.